Longeveron names Nirav Jhaveri as chief financial officer

Longeveron Inc. (NASDAQ: LGVN) announced on August 19, 2026 that it has appointed Nirav Jhaveri, CFA, as Chief Financial Officer, principal financial officer and principal accounting officer, effective August 17, 2026¹. He replaces Marie Washburn, who had stepped into the CFO role after the prior CFO's retirement; Washburn will remain with the company in her prior role of Vice President and Corporate Controller¹.

According to the filing, Jhaveri brings more than 25 years of biopharma and biotech leadership experience across public and private sectors, including work as CFO of gene-therapy and biotech companies, and most recently served as an independent strategic advisor to early-stage biotech companies on capital markets, positioning, investor targeting and fundraising¹. His prior CFO roles included Opus Genetics, Inc. from February 2024 to June 2025, Insilico Medicine from 2021 to 2023, and Journey Medical Corporation from 2020 to 2021, the last of which was pre-IPO during his tenure¹. Earlier in his career he worked in business development at Fortress Biotech, equity research at Citigroup, and investment banking at Bank of America, and holds a CFA charter.

Under his letter agreement, Jhaveri will receive an initial base salary of $400,000 per year and is eligible for a performance-based annual cash incentive with a target of 45 percent of base salary, along with equity awards under the company's incentive plan¹. He will also receive 300,000 restricted stock units vesting quarterly over three years.¹

CEO Steven Willard noted that the company's Phase 2b trial of laromestrocel for hypoplastic left heart syndrome is expected to produce top-line results in September of this year¹.